Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

Neurocrine Biosciences, Inc. has successfully completed its acquisition of Soleno Therapeutics, Inc. for a total equity value of $2.9 billion. The transaction, which was finalized on May 18, 2026, enhances Neurocrine's portfolio in the rare disease sector, particularly in endocrinology, by adding VYKAT™ XR, the first and only approved treatment for hyperphagia associated with Prader-Willi syndrome (PWS). This acquisition marks a significant step for Neurocrine as it aims to address unmet medical needs in this specialized area.

Soleno Therapeutics, known for its focus on rare genetic disorders, developed VYKAT™ XR (diazoxide choline) tablets, which received U.S. Food and Drug Administration (FDA) approval on March 26, 2025. VYKAT™ XR is indicated for treating hyperphagia in both adults and pediatric patients aged four years and older with PWS. This condition affects approximately 10,000 individuals in the United States and is characterized by severe hunger and food-seeking behaviors, leading to significant health risks and diminished quality of life. By integrating VYKAT™ XR into its product lineup, Neurocrine strengthens its commitment to providing innovative therapies for patients with rare diseases.

The strategic rationale behind this acquisition is clear: Neurocrine is enhancing its leadership position in the endocrinology space while expanding its offerings in rare diseases. The addition of VYKAT™ XR not only complements Neurocrine's existing therapies, such as INGREZZA® (valbenazine) and CRENESSITY® (crinecerfont), but also positions the company to capitalize on the growing market for rare disease treatments. The early adoption of VYKAT™ XR suggests strong commercial potential, further solidifying Neurocrine's foothold in a sector that is increasingly attracting investment and interest from pharmaceutical companies.

The broader market implications of this acquisition reflect a growing trend towards consolidation in the biopharmaceutical industry, particularly in the rare disease segment. As companies seek to diversify their portfolios and enhance their therapeutic offerings, strategic acquisitions like that of Soleno Therapeutics are likely to become more common. This trend not only indicates a robust pipeline of innovative treatments but also highlights the increasing recognition of the importance of addressing rare diseases, which often have limited treatment options available.

In conclusion, Neurocrine's acquisition of Soleno Therapeutics represents a significant advancement in the company's mission to deliver impactful therapies for patients with rare diseases. With the integration of VYKAT™ XR, Neurocrine is well-positioned to meet the needs of the PWS community while reinforcing its leadership in the endocrinology market. As the landscape for rare disease treatments continues to evolve, this acquisition may serve as a catalyst for further developments and investments in the sector.